PF-4800567

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H18ClN5O2
Molecular Weight	359.81
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=C2C(COC3=CC(Cl)=CC=C3)=NN(C4CCOCC4)C2=NC=N1

InChI

InChIKey=AUMDBEHGJRZSOO-UHFFFAOYSA-N

InChI=1S/C17H18ClN5O2/c18-11-2-1-3-13(8-11)25-9-14-15-16(19)20-10-21-17(15)23(22-14)12-4-6-24-7-5-12/h1-3,8,10,12H,4-7,9H2,(H2,19,20,21)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19458106 | https://www.ncbi.nlm.nih.gov/pubmed/20696890 | https://www.ncbi.nlm.nih.gov/pubmed/22089318 | https://www.ncbi.nlm.nih.gov/pubmed/27605609

PF 4800567 is a drug developed by Pfizer which acts as a selective potent inhibitor of CK1epsilon (IC(50) = 32 nM) with greater than 20-fold selectivity over CK1delta, and has mainly been used in the study of the casein kinase 1 enzymes in the regulation of circadian rhythm, as well as showing potential neuroprotective effects. PF 4800567 was found in animal studies to enhance responses to certain drugs of abuse such as methamphetamine and fentanyl, which suggests a role for CK1-ε in negative regulation of sensitivity to stimulant and opioid drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Casein kinase I epsilon 5 Target ID: CHEMBL4937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19458106	Inhibitor 8297		32.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period.	2009 Aug	19458106
Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes.	2010 Aug 24	20696890
IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation.	2011 Jun 2	21258417
Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids.	2012 Mar	22089318

Patents

Sample Use Guides

In Vivo Use Guide

Mice: 40 mg/kg, i.p.

Route of Administration: Intraperitoneal

In Vitro Use Guide

A significant lengthening of the period was observed at 1 uM PF 4800567 (approximately 10-fold CK1ε IC50; approximately 0.5- fold CK1δ IC50) in WT (0.9 ± 0.13 h increase in period) but not Ck1ε −/− -derived primary lung fibroblast cells (0.3 ± 0.3 h).

Name

Type

Language

PF-4800567

Code

English

1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[(3-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-

Systematic Name

English

PF4800567

Code

English

3-[(3-Chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Systematic Name

English

Code System Code Type Description

CAS

1188296-52-7